Upstream Bio, Inc. (UPB) has a consensus analyst rating of Hold, based on 1 analyst covering the stock. Of those, 0 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for UPB is $49.00, representing a +396.5% upside from the current price of $9.87. Price targets range from a low of $47.00 to a high of $51.00.
